Smallpox - Pipeline Review, H1 2019

Smallpox - Pipeline Review, H1 2019


  • Products Id :- GMDHC11071IDB
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Smallpox-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox-Pipeline Review, H1 2019, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smallpox-Overview

Smallpox-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smallpox-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smallpox-Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

CJ HealthCare Corp

EpiVax Inc

Fox Chase Chemical Diversity Center Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Smallpox-Drug Profiles

24a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brincidofovir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-40011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Smallpox-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox [ankara] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecovirimat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smallpox-Dormant Projects

Smallpox-Discontinued Products

Smallpox-Product Development Milestones

Featured News & Press Releases

Jan 18, 2019: Bavarian Nordic announces exercise of USD 44 million option by the U.S. Government under contract for freeze-dried MVA-BN Smallpox vaccine

Dec 21, 2018: Bavarian Nordic announces FDA acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine

Nov 01, 2018: SIGA announces Priority Review Voucher transaction totaling USD 80 million

Oct 05, 2018: Chimerix presents results from multiple ascending dose study of IV Brincidofovir at IDWeek

Oct 04, 2018: Landmark adVance study shows adenovirus burden correlates with mortality in pediatric allogeneic hematopoietic cell transplant recipients

Sep 19, 2018: Bavarian Nordic delivers Smallpox Vaccine to England in response to current Monkeypox Cases

Sep 10, 2018: SIGA Technologies awarded BARDA contract for TPOXX

Aug 21, 2018: Importance of Smallpox vaccination highlighted in biopreparedness exercise

Aug 09, 2018: Bavarian Nordic Granted EUR 30 Million loan from The European Investment Bank

Jul 13, 2018: FDA approves TPOXX as first drug to treat smallpox

Jul 05, 2018: Pivotal Trial Data for SIGA Technologies' Oral TPOXX Published in the New England Journal of Medicine

Jun 07, 2018: Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

Jun 05, 2018: Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

May 31, 2018: SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018

May 01, 2018: SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

List of Tables

Number of Products under Development for Smallpox, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Smallpox-Pipeline by Bavarian Nordic A/S, H1 2019

Smallpox-Pipeline by BioFactura Inc, H1 2019

Smallpox-Pipeline by CEL-SCI Corp, H1 2019

Smallpox-Pipeline by Chimerix Inc, H1 2019

Smallpox-Pipeline by CJ HealthCare Corp, H1 2019

Smallpox-Pipeline by EpiVax Inc, H1 2019

Smallpox-Pipeline by Fox Chase Chemical Diversity Center Inc, H1 2019

Smallpox-Pipeline by SIGA Technologies Inc, H1 2019

Smallpox-Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019

Smallpox-Dormant Projects, H1 2019

Smallpox-Dormant Projects, H1 2019 (Contd..1), H1 2019

Smallpox-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

CJ HealthCare Corp

EpiVax Inc

Fox Chase Chemical Diversity Center Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Smallpox Therapeutic Products under Development, Key Players in Smallpox Therapeutics, Smallpox Pipeline Overview, Smallpox Pipeline, Smallpox Pipeline Assessment

select a license
Single User License
USD 2000 INR 138000
Site License
USD 4000 INR 276000
Corporate User License
USD 6000 INR 414000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com